Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection
复制标题
DOI：
10.1056/nejmoa013376
复制
发表时间：
2002-07-11
影响因子：
158.5
通讯作者：
Troussard, X
中科院分区：
文献类型：
--
作者：
Hermine, O;Lefrère, F;Troussard, X
背景 一些流行病学研究表明丙型肝炎病毒 (HCV) 感染与某些 B 细胞非霍奇金淋巴瘤之间存在联系。我们在一名伴有绒毛淋巴细胞的脾淋巴瘤患者在 HCV 感染的抗病毒治疗后出现血液学反应后进行了这项研究。方法 9 例患有绒毛淋巴细胞的脾淋巴瘤和 HCV 感染的患者接受干扰素 α-2b（300 万国际单位，每周 3 次）单独治疗或联合利巴韦林（每天 1000 至 1200 mg）治疗。结果与 6 名接受类似治疗且 HCV 感染检测呈阴性的伴有绒毛淋巴细胞的脾淋巴瘤患者的结果进行了比较。结果 在接受干扰素 α 治疗的 9 名 HCV 感染患者中，7 名在可检测到的 HCV RNA 消失后完全缓解。另外两名患者在添加利巴韦林后出现部分和完全缓解，并且可检测到的 HCV RNA 消失。当血液中再次检测到 HCV RNA 载量时，一名患者病情复发。相比之下，六名HCV阴性患者均未对干扰素治疗产生反应。 结论 对于感染HCV的伴有绒毛淋巴细胞的脾淋巴瘤患者，干扰素治疗可导致淋巴瘤消退。
Background Some epidemiologic studies suggest a link between hepatitis C virus (HCV) infection and some B-cell non-Hodgkin's lymphomas. We undertook this study after a patient with splenic lymphoma with villous lymphocytes had a hematologic response after antiviral treatment of HCV infection.Methods Nine patients who had splenic lymphoma with villous lymphocytes and HCV infection were treated with interferon alfa-2b (3 million IU three times per week) alone or in combination with ribavirin (1000 to 1200 mg per day). The outcomes were compared with those of six similarly treated patients with splenic lymphoma with villous lymphocytes who tested negative for HCV infection.Results Of the nine patients with HCV infection who received interferon alfa, seven had a complete remission after the loss of detectable HCV RNA. The other two patients had a partial and a complete remission after the addition of ribavirin and the loss of detectable HCV RNA. One patient had a relapse when the HCV RNA load again became detectable in blood. In contrast, none of the six HCV-negative patients had a response to interferon therapy.Conclusions In patients with splenic lymphoma with villous lymphocytes who are infected with HCV, treatment with interferon can lead to regression of the lymphoma.